Journals / Turkish Journal of Gastroenterology / 2000 / Cilt: 11 - Sayı: 1

Helicobacter ilişkili gastrit ve peptik ülser tedavisinde lansoprazol ve omeprazol içeren 3'lü kombinasyonların karşılaştırılması

A comparison of lansoprazole and omeprazole based triple combinations for the treatment of Helicobacter pylori associated gastritis and peptic ulcer

Pages
25–29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A considerable reduction in gastric activity and H. pylori intensity was noted in all patients with duodenal ulcers.In conclusion, both triple combinations were of similar efficacy in eradication of H. pylori associated peptic disorders.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This study compares the efficacy of two triple combination regimens, including omeprazole or lansoprazole, for the treatment of Helicobacter pylori (H.
📊
Key Findings & Data:The first group (mean age: 46±12; 11 M, 10 F) received lansoprazole 30 mg. b.i.d. for one month, clarithromycin 250 mg. t.i.d. daily for 15 days and amoxycillin 1gr. b.i.d. for 15 days (LCA).
💡
Conclusion & Impact:A considerable reduction in gastric activity and H. pylori intensity was noted in all patients with duodenal ulcers.In conclusion, both triple combinations were of similar efficacy in eradication of H. pylori associated peptic disorders.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Omeprazol · İlaç tedavisi · kombinasyon

Abstract

This study compares the efficacy of two triple combination regimens, including omeprazole or lansoprazole, for the treatment of Helicobacter pylori (H. Pylori) associated gastritis or duodenal ulcer.Forty-two patients with endoscopically proven gastritis and /or peptic ulcer were randomly divided into two groups . The first group (mean age: 46±12; 11 M, 10 F) received lansoprazole 30 mg. b.i.d. for one month, clarithromycin 250 mg. t.i.d. daily for 15 days and amoxycillin 1gr. b.i.d. for 15 days (LCA). The second group was given omeprazole 20 mg. b.i.d. for 1 month in addition to the same antibiotic combination as the first group (OCA). After this treatment, both groups received maintenance therapy of famotidine 40 mg daily for six weeks, followed by endoscopic examination. Chi-square and Mann-Whitney U tests were used for statistical analysis. Helicobacter pylori eradication rates were 67% with LCA and 76% with OCA. Gastric activity decreased significantly with eradication in both groups, including OCA patients in whom H. pylori eradication was not achieved. There were no significant differences between the two combinations with respect to eradication, reduction in gastric activity or H.pylori intensity. All duodenal ulcers in both groups were observed to heal completely with treatment, regardless of H.pylori eradication in both groups. A considerable reduction in gastric activity and H. pylori intensity was noted in all patients with duodenal ulcers.In conclusion, both triple combinations were of similar efficacy in eradication of H. pylori associated peptic disorders. Neither combination yielded superior results as reported in previous studies. The long treatment period and high cost are major drawbacks for both combinations.

Özet

Bu çalışmada gastrit ve/veya duodenal ülserli hastalarda lansoprazol, amoksisilin, klaritromisin ve omeprazol, amoksisilin, klaritromisin içeren iki farklı tedavinin Helicobacter pylori (H. Pylori) eradikasyonu açısından etkinliği araştırılmıştır.Endoskopik incelemelerinde yalnızca gastrit (n: 22, %52.4) ve/veya peptik ülser (n:20, %47.6) saptanan toplam 42 hasta 2 tedavi koluna randomize edildiler. Birinci grubta yer alan hastalara (ort. yaş: 46±12; 10 K, 11 E) 1 ay boyunca 2x30 mg/gün lansoprazol, 2. Grupta yer alan hastalara (ort. yaş: 41±12; 11 K, 10 E) ise 2x20 mg/gün omeprazol uygulandı. Tüm hastalara son 15 gün 2x1 gr/gün amoksisilin ve 3x250 mg/gün klaritromisin verildi. Daha sonra famotidin 40 mg/gün ile idame tedavisi uygulandı. Tedavi öncesinde ve 6 hafta sonra tüm hastalar korpus ve antrumdan 2 adet biyopsi alınarak gastritis aktivasyonu ve H. pylori yoğunluğu açısından değerlendirildi. İstatistiksel incelemeler için ki-kare ve Mann-Whitney U testleri kullanıldı. Lansoprazol içeren tedavi kolunda eradikasyon oranı %67 (n:14), omeprazol kolunda ise %76 (n:16) olarak saptandı. İki grup arasında eradikasyon açısından anlamlı bir farklılık bulunmadı. Birinci grupta eradikasyon sağlanan olgularda gastritis aktivitesinde anlamlı gerileme izlenmesine rağmen, eradikasyon sağlanmayanlarda gastritis aktivitesinde anlamlı bir azalma saptanmadı. Oysa 2. grupta tüm hastalarda tedavi ile gastritis aktivitesi belirgin olarak azaldı. Her iki grupta tedavi ile tüm duodenal ülserler iyileşti. Tüm duodenal ülserli hastalarda H. pylori endikasyonu sağlanmasına ek olarak gastritis aktivitesi ve H. pylori yoğunluğunda da belirgin gerileme gözlendi. Sonuç olarak omeprazol kombinasyonunda daha yüksek oranda eradikasyon elde edilmesine rağmen, iki grup arasında eradikasyon, gastritis aktivitesinde ve H. pylori yoğunluğundaki gerileme yönlerinden anlamlı bir farklılık gözlenmemiştir. Her iki tedavi seçeneği de %80'in altında eradikasyon oranı ile çok etkin bir sonuç vermemiştir. Ayrıca uzun süreli kullanım zorunluğu ve pahalı olmaları başlıca dezavantajlarını oluşturmaktadır.

🔖

Cite This Article

ERALP, Y., DOBRUCALI, A., BAĞATUR, N., ÇELİK, A., DAVUTOĞLU, C., TUNCER, M., BAL, K., GÖKSEL, S., UZUNİSMAİL, H., YURDAKUL, İ., OKTAY, E. (2000). Helicobacter ilişkili gastrit ve peptik ülser tedavisinde lansoprazol ve omeprazol içeren 3'lü kombinasyonların karşılaştırılması. Turkish Journal of Gastroenterology, Cilt: 11 - Sayı: 1, 25–29. https://ajindex.com/articles/410545

References (16)

  1. . Mobley LT, Defining H. pylori as a pathogen: Strain heterogenity and virulance. Am J Med 1996
  2. . Shamburek RD, Schubert ML. Control of gastric acid secretion. Gastroenterol Clin North Am 1992
  3. . Freston JW. Long term acid control and proton pump inhibitors: Interactions and safety issues in perspective. Am J Gastroenterol 1997
  4. . Hunt RH. Eradication of H. pylori infection. Am J Med 1996
  5. . Daw MA, Deegan P, Leen E, O’Morain C. Short report: The effect of omeprazole on H. pylori and associated gastritis. Aliment Pharmacol Ther 1991
  6. . Alam K, Schubert T, Bologna SP, Ma CK. Increased density of H. pylori on antral biopsy is associated with severity of acute and chronic inflammation and likelihood of duodenal ulceration. Am J Gastroenterol 1992
  7. . Behrens R, Lang T, Keller KM, et al. Dual versus triple therapy of H. Pylori infection: results of a multicenter study. Arch Dis Child 1999
  8. . Delchier JC, Elamine I, Goldfain, et al. Omeprazole-amoxycillin vs omeprazole-amoxycillin-clarithromycin in the eradication of H. pylori. Aliment Pharmacol Ther 1996
  9. . Axon ATR, Moayyedi P. Eradication of H. pylori: Omeprazole in combination with antibiotics. Scand J Gastroenterol 1996
  10. . Lind T, Veldhuyzen von Zanten S, Unge P, et al.: Eradication of H. pylori using 1-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996
  11. . Unge P. Review of H. pylori eradication regimens. Scand J Gastroenterol 1996
  12. . Gisbert JP. Lansoprazole: a review of its role in H. pylori eradication therapy. Rev Esp Enferm Dig 1999
  13. . Harris AW, Misiewicz JJ, Bardhan KD, et al. Incidence of ulcer healing after 1 week of PPI triple therapy for eradication of H. pylori: The Lansoprazole Helicobacter Study Group. Aliment Pharmacol Ther 1998
  14. . Spinzi GC, Bierti L, Bortali A, et al. Comparison of omeprazole and lansoprazole in short term triple therapy for H. pylori infection. Aliment Pharmacol Ther 1998
  15. . Lamoulette H, Coyle R, Zerbib F, et al. Dual therapy using a double dose of lansoprazole and amoxycillin vs. triple therapy using a double dose of lansoprazole, amoxycillin and clarithromycin to eradicate H. pylori infection: results of a prospective randomized study. Am J Gastroenterol 1998
  16. . Doğan Ü, Tunçer C, Dursun A, et al.